Results 221 to 230 of about 1,115,426 (335)

TRIM38 Suppresses the Progression of Colorectal Cancer via Enhancing CCT6A Ubiquitination to Inhibit the MYC Pathway

Advanced Science, EarlyView.
This study reveals the tumor‐suppressive role of TRIM38 in colorectal cancer (CRC). TRIM38 is downregulated through DNA hypermethylation and correlates with unfavorable clinical features and poor prognosis. Mechanistically, TRIM38 inhibits CRC progression by promoting K48‐linked ubiquitination of CCT6A, leading to the destabilization of c‐Myc.
Yue Zhang, Xinyu Tan, Lu Wang, Dongjian Ji, Chuan Zhang, Wen Peng, Renzhong Zhu, Xiaowei Wang, Jiahui Zhou, Yifei Feng, Yueming Sun   +10 more
wiley   +1 more source

Colo-cutaneous fistula: an unusual complication after hemilaminectomy and microdiscectomy. [PDF]

J Surg Case Rep
Zappala I, Choi JDW, Soliman B, Pathma-Nathan N.   +3 more
europepmc   +1 more source

Caspase‐6/Gasdermin C‐Mediated Tumor Cell Pyroptosis Promotes Colorectal Cancer Progression Through CXCL2‐Dependent Recruitment of Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
Hypoxic and low‐glucose conditions in tumor tissues trigger colorectal tumor cell pyroptosis via sequential activation of the Caspase‐1/Caspase‐6/GSDMC axis. High mobility group box 1 (HMGB1), released from GSDMC‐mediated pyroptotic tumor cells, upregulates CXCL2 expression in adjacent tumor cells, thereby recruiting myeloid‐derived suppressor cells ...
Hanchao Gao, Yikun Yao, Weilong Li, Zigan Xu, Wenjun Hu, Kewang Luo, Peishan Chen, Wanjing Shang, Shaodong Luan, Guojun Shi, Mengtao Cao, Pengfei Chen   +11 more
wiley   +1 more source

Orally Administered Functional Polyphenol‐Nanozyme‐Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis

Advanced Science, EarlyView.
This study presents a novel polyphenol‐nanozyme‐armored probiotic system (ECA@EcN) for enhanced treatment of inflammatory bowel disease (IBD). By integrating chitosan‐modified epigallocatechin gallate (EGCG‐CS) with gold nanozymes, the system effectively scavenges ROS, improves probiotic viability, and restores gut microbiota balance.
Yong Zhu, Ziqu Fang, Jie Bai, Longhui Wang, Jiaqing Chen, Zehua Zhang, Qiang Wang, Weiwei Sheng, Xueyin Pan, Zhenyuan Gao, Dengqiu Xu, Pengkai Wu, Beicheng Sun   +12 more
wiley   +1 more source

Editorial: Aging and the microbiome. [PDF]

Front Aging
Villicaña C, Moretti CH, Carbonero F.
europepmc   +1 more source

The Novel Dual GIP and GLP‐1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism

Advanced Science, EarlyView.
Tirzepatide, a dual GIP/GLP‐1 receptor agonist for diabetes, suppresses colorectal cancer growth by targeting glucose metabolism. It inhibits cancer cell proliferation, promotes apoptosis, and induces tumor regression. It reduces glucose uptake and destabilizes HIF‐1α for degradation to downregulate PFKFB3/PFK‐1 enzymes, thus contributing to the ...
Yikai Zhang, Yi Xie, Shenglong Xia, Xinnuo Ge, Jiaying Li, Fang Liu, Fan Jia, Shengyao Wang, Qiao Zhou, Menghan Gao, Weihuan Fang, Chao Zheng   +11 more
wiley   +1 more source

Inulin as a Biopolymer; Chemical Structure, Anticancer Effects, Nutraceutical Potential and Industrial Applications: A Comprehensive Review. [PDF]

Polymers (Basel)
Karimi I, Ghowsi M, Mohammed LJ, Haidari Z, Nazari K, Schiöth HB.   +5 more
europepmc   +1 more source

Positive Feedback Regulation between KLF5 and XPO1 Promotes Cell Cycle Progression of Basal like Breast Cancer

Advanced Science, EarlyView.
KLF5 is highly expressed in BLBC patients and promotes Cyclin D1 and XPO1 transcription, ultimately leading to the inactivation of RB1. Both XPO1 inhibitor (KPT‐330) and CDK4/6 inhibitor (Palbociclib) can enhance RB1 activity and exert antitumor effects. It has been proved that the combination of KPT‐330 and Palbociclib can inhibit the proliferation of
Yu Tang, Rui Liu, Jing Zhu, Qian He, Chenglong Pan, Zhongmei Zhou, Jian Sun, Fubing Li, Longlong Zhang, Yujie Shi, Jing Yao, Dewei Jiang, Ceshi Chen   +12 more
wiley   +1 more source

Telocytes in inflammatory bowel diseases: contributions to pathology and therapeutic potentials. [PDF]

Front Cell Dev Biol
Panganiban RP, McAninch C, Chulkina M, Pinchuk IV.   +3 more
europepmc   +1 more source